Regentis Biomaterials (RGNT) Stock Price, News & Analysis

Company Overview

Regentis Biomaterials Ltd. is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee.

Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses.

The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology. Regentis Biomaterials is headquartered in Israel and has pursued development for international orthopedic markets. Publicly available information about its broader product pipeline and current leadership is limited.

Key Stats

• Today's Range: $1.59 to $1.67
• 50-Day Range: $1.60 to $2.23
• 52-Week Range: $1.23 to $15.50
• Volume: 33,393 shs
• Average Volume: 66,475 shs
• Market Capitalization: $8.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Regentis Biomaterials Stock Analysis - MarketRank™

Regentis Biomaterials scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Regentis Biomaterials has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regentis Biomaterials has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the float of Regentis Biomaterials has been sold short.

Short Interest Ratio / Days to Cover

Regentis Biomaterials has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regentis Biomaterials has recently decreased by 42.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regentis Biomaterials does not currently pay a dividend.

Dividend Growth

Regentis Biomaterials does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Regentis Biomaterials has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Regentis Biomaterials this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regentis Biomaterials insiders have not sold or bought any company stock.

Percentage Held by Institutions

Regentis Biomaterials has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/11/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:RGNT
• CIK: 1912966
• Web: www.regentis.co.il
• Phone: 972-9960-1917
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.62
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 5,180,000
• Free Float: N/A
• Market Cap: $8.42 million
• Optionable: N/A
• Beta: N/A